Latest Insider Transactions at Becton Dickinson & CO (BDX)
This section provides a real-time view of insider transactions for Becton Dickinson & CO (BDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BECTON DICKINSON & CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BECTON DICKINSON & CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Roland Goette EVP and President EMEA |
SELL
Open market or private sale
|
Direct |
3,300
-8.16%
|
$778,800
$236.58 P/Share
|
|
May 13
2024
|
Roland Goette EVP and President EMEA |
SELL
Open market or private sale
|
Direct |
3,300
-6.46%
|
$782,100
$237.11 P/Share
|
|
Apr 30
2024
|
Michael David Garrison EVP & President Medical |
SELL
Open market or private sale
|
Direct |
1,715
-24.17%
|
$397,880
$232.81 P/Share
|
|
Apr 04
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,921
-10.49%
|
-
|
|
Mar 14
2024
|
Thomas J Spoerel SVP,Controller&Chief Acct Off |
SELL
Open market or private sale
|
Direct |
282
-11.02%
|
$67,116
$238.29 P/Share
|
|
Mar 01
2024
|
Thomas J Spoerel SVP,Controller&Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
36
-1.39%
|
-
|
|
Mar 01
2024
|
Michael David Garrison EVP & President Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-2.45%
|
-
|
|
Mar 01
2024
|
Antoine C Ezell EVP, President NA & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-2.94%
|
-
|
|
Jan 23
2024
|
Timothy M Ring Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+1.56%
|
-
|
|
Jan 23
2024
|
Bertram L Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+2.49%
|
-
|
|
Jan 23
2024
|
Joanne Waldstreicher Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+40.49%
|
-
|
|
Jan 23
2024
|
Claire Fraser Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+3.81%
|
-
|
|
Jan 23
2024
|
Jeffrey William Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+13.91%
|
-
|
|
Jan 23
2024
|
Christopher Ian Montague Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+4.04%
|
-
|
|
Jan 23
2024
|
Catherine M Burzik Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+6.36%
|
-
|
|
Jan 23
2024
|
William M Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+26.38%
|
-
|
|
Jan 23
2024
|
Carrie L Byington Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+23.97%
|
-
|
|
Jan 23
2024
|
R Andrew Eckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+9.97%
|
-
|
|
Jan 03
2024
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
44
-0.77%
|
-
|
|
Dec 11
2023
|
Michael David Garrison EVP & President Medical |
SELL
Open market or private sale
|
Direct |
1,239
-14.55%
|
$287,448
$232.46 P/Share
|
|
Nov 28
2023
|
Richard Byrd EVP & President Interventional |
SELL
Open market or private sale
|
Direct |
2,156
-34.35%
|
$513,128
$238.47 P/Share
|
|
Nov 26
2023
|
David Hickey EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
1,663
+22.1%
|
-
|
|
Nov 26
2023
|
Thomas J Spoerel SVP,Controller&Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
365
-12.34%
|
-
|
|
Nov 26
2023
|
Thomas J Spoerel SVP,Controller&Chief Acct Off |
BUY
Grant, award, or other acquisition
|
Direct |
1,132
+17.46%
|
-
|
|
Nov 26
2023
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
258
-1.39%
|
-
|
|
Nov 26
2023
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,659
+8.2%
|
-
|
|
Nov 26
2023
|
Pavan Kumar Mocherla EVP & President Greater Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-3.4%
|
-
|
|
Nov 26
2023
|
Pavan Kumar Mocherla EVP & President Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
751
+17.63%
|
-
|
|
Nov 26
2023
|
Michael David Garrison EVP & President Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
1,646
-16.2%
|
-
|
|
Nov 26
2023
|
Michael David Garrison EVP & President Medical |
BUY
Grant, award, or other acquisition
|
Direct |
5,002
+22.29%
|
-
|
|
Nov 26
2023
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
812
-5.67%
|
-
|
|
Nov 26
2023
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,325
+18.84%
|
-
|
|
Nov 26
2023
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
1,509
-19.38%
|
-
|
|
Nov 26
2023
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
4,341
+24.97%
|
-
|
|
Nov 26
2023
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
149
-2.53%
|
-
|
|
Nov 26
2023
|
David Shan EVP and Chief ISC Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,408
+18.65%
|
-
|
|
Nov 26
2023
|
Michelle Quinn EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
440
-8.16%
|
-
|
|
Nov 26
2023
|
Michelle Quinn EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,115
+17.8%
|
-
|
|
Nov 26
2023
|
Roland Goette EVP and President EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
213
-1.15%
|
-
|
|
Nov 26
2023
|
Roland Goette EVP and President EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
3,190
+7.9%
|
-
|
|
Nov 26
2023
|
Antoine C Ezell EVP, President NA & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,654
-14.69%
|
-
|
|
Nov 26
2023
|
Antoine C Ezell EVP, President NA & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,069
+16.09%
|
-
|
|
Nov 16
2023
|
Roland Goette EVP and President EMEA |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,751
-10.2%
|
$411,485
$235.07 P/Share
|
|
Nov 16
2023
|
Roland Goette EVP and President EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
3,544
+17.11%
|
$379,208
$107.12 P/Share
|
|
Sep 07
2023
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
601
-5.18%
|
-
|
|
Sep 05
2023
|
Richard Byrd EVP & President Interventional |
SELL
Open market or private sale
|
Direct |
459
-11.76%
|
$125,766
$274.48 P/Share
|
|
Sep 01
2023
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-5.24%
|
-
|
|
Sep 01
2023
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
353
-2.95%
|
-
|
|
Aug 28
2023
|
Claire Fraser Director |
SELL
Open market or private sale
|
Direct |
848
-3.78%
|
$238,288
$281.66 P/Share
|
|
Aug 11
2023
|
David Hickey EVP & President, Life Sciences |
SELL
Open market or private sale
|
Direct |
2,974
-41.46%
|
$823,798
$277.85 P/Share
|